Short Interest in Lipocine Inc. (NASDAQ:LPCN) Decreases By 41.2%

Lipocine Inc. (NASDAQ:LPCN) saw a large decline in short interest in May. As of May 15th, there was short interest totaling 102,133 shares, a decline of 41.2% from the April 30th total of 173,716 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily volume of 103,762 shares, the short-interest ratio is presently 1.0 days.

Analysts Set New Price Targets

LPCN has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a research note on Friday, March 27th. Wall Street Zen cut shares of Lipocine from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Lipocine presently has a consensus rating of “Hold” and a consensus price target of $15.00.

Lipocine Stock Performance

LPCN opened at $2.28 on Tuesday. The stock has a market capitalization of $18.79 million, a P/E ratio of -1.22 and a beta of 0.48. The company’s 50-day simple moving average is $3.25 and its two-hundred day simple moving average is $5.62. Lipocine has a 52-week low of $1.81 and a 52-week high of $12.37.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.16 million. Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. Research analysts forecast that Lipocine will post -1.91 EPS for the current fiscal year.

Insider Transactions at Lipocine

In other news, Director John W. Higuchi purchased 123,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were bought at an average price of $2.05 per share, for a total transaction of $252,150.00. Following the purchase, the director directly owned 163,797 shares in the company, valued at approximately $335,783.85. This trade represents a 301.49% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mahesh V. Patel purchased 25,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was purchased at an average price of $2.03 per share, for a total transaction of $50,750.00. Following the purchase, the chief executive officer owned 160,679 shares in the company, valued at $326,178.37. This represents a 18.43% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 213,000 shares of company stock worth $434,600. 6.35% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lipocine

Several institutional investors have recently made changes to their positions in the business. Stempoint Capital LP bought a new position in shares of Lipocine in the 1st quarter worth approximately $1,282,000. ADAR1 Capital Management LLC bought a new position in shares of Lipocine in the 1st quarter worth approximately $185,000. Eversept Partners LP bought a new position in shares of Lipocine in the 1st quarter worth approximately $2,357,000. Exome Asset Management LLC bought a new position in shares of Lipocine in the 1st quarter worth approximately $486,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Lipocine by 57.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after purchasing an additional 6,982 shares during the period. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.